Pharmacogenomic Variability in Antiplatelet Therapy: Clinical Implications

Pharmacogenomic variability significantly influences the response to antiplatelet therapy, particularly with drugs like clopidogrel, prasugrel, and ticagrelor, which are commonly used to prevent thrombotic events in patients with cardiovascular diseases. Genetic variations in drug-metabolizing enzymes, such as cytochrome P450 2C19 (CYP2C19), can affect the efficacy of clopidogrel, leading to suboptimal platelet inhibition and an increased risk of adverse cardiovascular outcomes. This review explores the clinical implications of pharmacogenomic variability in antiplatelet therapy, focusing on how genetic testing can guide individualized treatment decisions. We examine the role of genetic polymorphisms in CYP2C19 and other genes involved in drug metabolism and platelet function, including the impact on both drug efficacy and safety. The review also discusses the clinical utility of genotyping in identifying patients who are poor or ultrarapid metabolizers of clopidogrel, and how alternative therapies may be considered for these patients. Furthermore, we highlight the challenges of implementing pharmacogenomic testing in routine clinical practice, such as cost, accessibility, and physician awareness. Finally, the article addresses the potential for precision medicine in antiplatelet therapy, offering insights into how genetic-based approaches could optimize treatment outcomes and reduce adverse effects for patients with cardiovascular disease.